FUSN
Closed
Fusion Pharmaceuticals inc
21.55
+0.03 (+0.14%)
Last Update: 04 Jun 2024 23:00:00
Yesterday: 21.52
Day's Range: 21.55 - 21.55
Send
sign up or login to leave a comment!
When Written:
3.74
Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that is focused on developing targeted alpha therapeutics (TATs) for the treatment of cancer. TATs are a new class of precision oncology therapeutics that use alpha particle radiation to selectively target and destroy cancer cells while sparing healthy tissue. The company's lead product candidate, FPI-1434, is a TAT designed to target and destroy cancer cells that express the fibroblast growth factor receptor 3 (FGFR3) protein. FPI-1434 is currently being evaluated in a Phase 1 clinical trial for the treatment of advanced solid tumors. Fusion Pharmaceuticals is headquartered in Hamilton, Ontario, Canada, and was founded in 2014. The company went public in 2020 and is listed on the Nasdaq Global Market under the symbol "FUSN".
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








